SBIO stock forecast, quote, news & analysis

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX).

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 2.05B. The market cap for tickers in the group ranges from 38.63M to 13.5B. SMMT holds the highest valuation in this group at 13.5B. The lowest valued company is RAPT at 38.63M.

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was -12%. For the same ETF, the average monthly price growth was -7%, and the average quarterly price growth was 8%. MDXG experienced the highest price growth at 23%, while RAPT experienced the biggest fall at -62%.

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 35%. For the same stocks of the ETF, the average monthly volume growth was 91% and the average quarterly volume growth was 84%